We are live on ! Find out more
TCRR

TCR2 Therapeutics Inc. Common Stock
TCRR

Delisted

TCRR was delisted on the 31st of May, 2023.

Back to rankings

129 hedge funds and large institutions have $834M invested in TCR2 Therapeutics Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 60 increasing their positions, 29 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

107% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 29

79% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 14

9% more funds holding

Funds holding: 118 → 129 (+11)

22% less capital invested

Capital invested by funds: $1.07B → $834M (-$236M)

28% less call options, than puts

Call options by funds: $1.92M | Put options by funds: $2.67M

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

Holders
129
Holders Change
+11
Holders Change %
+9.32%
% of All Funds
2.26%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.04%
New
25
Increased
60
Reduced
29
Closed
14
Calls
$1.92M
Puts
$2.67M
Net Calls
-$745K
Net Calls Change
-$945K

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$33M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$32.2M
3
Victory Capital Management
Victory Capital Management
Texas
+$27.9M
4
FLAM
First Light Asset Management
Minnesota
+$22.5M
5
RG
Redmile Group
California
+$21.2M

Top Sellers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
-$71.3M
2
PHS
PFM Health Sciences
California
-$24M
3
Citadel Advisors
Citadel Advisors
Florida
-$13.5M
4
MWNA
Marshall Wace North America
New York
-$13.1M
5
Millennium Management
Millennium Management
New York
-$9.18M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Advisers
26
Two Sigma Advisers
New York
$6.54M +$6.34M +232,400 +365%
O
27
OrbiMed
New York
$5.5M – – –
TCM
28
Tekla Capital Management
Massachusetts
$5.21M +$6.43M +235,808 New
ACM
29
Altium Capital Management
New York
$4.62M +$3.68M +135,139 +183%
Charles Schwab
30
Charles Schwab
California
$4.15M +$775K +28,429 +18%
BBA
31
Baker Bros. Advisors
New York
$3.9M +$1.79M +65,573 +59%
SCM
32
Silverarc Capital Management
Massachusetts
$3.43M +$522K +19,145 +14%
SEI Investments
33
SEI Investments
Pennsylvania
$3.42M -$1.83M -67,168 -30%
Citigroup
34
Citigroup
New York
$3.39M +$3.86M +141,700 +1,187%
Renaissance Technologies
35
Renaissance Technologies
New York
$3.28M +$4.05M +148,500 New
Millennium Management
36
Millennium Management
New York
$3.27M -$9.18M -336,585 -69%
SCM
37
Soleus Capital Management
Connecticut
$3.14M -$1.57M -57,730 -29%
IC
38
Ikarian Capital
Texas
$3.01M +$409K +15,000 +12%
MAP
39
Moody Aldrich Partners
Massachusetts
$2.77M +$54.6K +2,001 +2%
Bank of New York Mellon
40
Bank of New York Mellon
New York
$2.76M -$7.77K -285 -0.2%
N
41
Nuveen
North Carolina
$2.61M -$534K -19,590 -14%
Rafferty Asset Management
42
Rafferty Asset Management
New York
$2.55M +$2.94M +107,759 +1,408%
Federated Hermes
43
Federated Hermes
Pennsylvania
$2.49M +$1.38M +50,535 +81%
Deutsche Bank
44
Deutsche Bank
Germany
$2.3M +$8.04K +295 +0.3%
FAM
45
Fred Alger Management
New York
$2.05M -$589K -21,616 -19%
D.E. Shaw & Co
46
D.E. Shaw & Co
New York
$1.95M +$2.41M +88,390 New
Squarepoint
47
Squarepoint
New York
$1.9M +$1.79M +65,772 +326%
SW
48
SVB Wealth
Massachusetts
$1.6M – – –
Wells Fargo
49
Wells Fargo
California
$1.35M +$700K +25,668 +72%
GH
50
GAM Holding
Switzerland
$1.29M +$1.59M +58,343 New
1
2
3 4 5

TCRR Hedge Fund Activity: Q1 2021 in Review

129 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in TCR2 Therapeutics Inc. Common Stock (TCRR) for Q1 2021, worth a combined $834M — down 22% from $1.07B a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new TCRR positions and 14 closed out — a net gain of 11 holders — while 60 added to existing stakes and 29 trimmed.

The largest buyer was State Street, adding an estimated $33M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $71.3M sold.

  • 129 institutional investors held TCR2 Therapeutics Inc. Common Stock (TCRR) as of Q1 2021, up from 118 in Q4 2020.
  • Funds reported $834M of TCR2 Therapeutics Inc. Common Stock stock for Q1 2021, down 22% quarter-over-quarter.
  • 25 funds opened new TCR2 Therapeutics Inc. Common Stock positions in Q1 2021 and 14 closed out, a net change of +11 holders.
  • The largest TCR2 Therapeutics Inc. Common Stock buyer in Q1 2021 was State Street, an estimated $33M added.
  • The largest TCR2 Therapeutics Inc. Common Stock seller in Q1 2021 was Consonance Capital Management, an estimated $71.3M sold.

Based on aggregated 13F filings for Q1 2021.